Gene Expression Attribute
Introduction
A gene expression attribute refers to any measurable characteristic or trait that is influenced by the degree to which genes are active within a cell or tissue. This fundamental biological process, known as gene expression, involves converting the information encoded in a gene into a functional product, such as a protein or an RNA molecule. The levels of these gene products can vary significantly between individuals and across different biological contexts, leading to diverse attributes and phenotypes.
Biological Basis
The regulation of gene expression is a complex and finely tuned process. Genetic variations, particularly single nucleotide polymorphisms (SNPs), can act as expression quantitative trait loci (eQTLs) by influencing the transcription levels of genes, whether they are located nearby (cis-acting) or at a distance (trans-acting). [1] Researchers identify these associations by testing the relationship between specific SNPs and transcript expression levels, often utilizing statistical methods such as linear regression. [1] Functional annotation of these SNPs helps to understand their consequences on genes and their regulatory functions. [2] These genetic influences can impact various cellular mechanisms, including transcription factor binding and the overall enhancement of gene activity. [3] The association between genetic variants and cis-gene expression, where the variant is located close to the gene it regulates, has been observed across distinct human tissues. [4]
Clinical Relevance
Understanding gene expression attributes holds significant clinical relevance, as altered gene expression is frequently implicated in the development and progression of various diseases. Studies investigate how transcript expression changes between individuals with and without certain diseases, particularly for genes containing significant SNPs. [5] For example, research has explored the effect of specific SNPs on gene expression in critical tissues like the dorsolateral prefrontal cortex and temporal cortex, which is pertinent to neurodegenerative conditions such as Alzheimer's disease. [5] Furthermore, gene expression patterns can elucidate the functional impact of polygenic risk for complex conditions like schizophrenia [6] and SNPs influencing gene expression have been linked to processes relevant to neurodevelopment and immunology. [3]
Social Importance
The study of gene expression attributes contributes broadly to human health and societal well-being by advancing our understanding of the genetic underpinnings of complex traits and diseases. By identifying the genetic variants that modulate gene expression, scientists can develop more precise diagnostic tools, predict individual susceptibility to diseases, and inform the development of targeted therapies. This knowledge is crucial for the ongoing advancement of personalized medicine, allowing for interventions tailored to an individual's unique genetic and expression profile.
Methodological and Statistical Constraints
Studies investigating gene expression attributes can face limitations in statistical power, particularly when attempting to detect genetic variants with small effect sizes through conventional single-marker association analyses . Many of these variants can act as expression quantitative trait loci (eQTLs), affecting the levels of gene transcription or protein production. [1] For instance, variants in protein-coding genes like _ARHGAP15_, _COG2_, and _NTM_ can have widespread effects on cellular function. _ARHGAP15_ encodes a Rho GTPase activating protein, critical for regulating cell motility and cytoskeletal dynamics, and a variant such as rs10928182 could alter its enzymatic activity, thereby impacting cell migration and adhesion pathways. Similarly, _COG2_ is a component of the conserved oligomeric Golgi complex, essential for maintaining Golgi structure and trafficking, making rs9651127 a potential modulator of protein glycosylation and sorting efficiency. _NTM_ (Neurotrimin) functions as a cell adhesion molecule in the nervous system, integral to neuronal development and synapse formation, suggesting that rs56344002 could influence neural connectivity and brain function.
Further exploring protein-coding genes, _CARD14_, _SLC35F4_, and _RNF150_ highlight diverse cellular roles. _CARD14_ is a key scaffold protein involved in activating the NF-κB signaling pathway, a central regulator of immune and inflammatory responses; thus, rs11652075 might modulate an individual's inflammatory susceptibility. _SLC35F4_ is a member of the solute carrier family, typically responsible for transporting specific substances across cell membranes, which are vital for cellular metabolism and detoxification; a variant like rs878085 could alter transport kinetics and cellular nutrient uptake. _RNF150_, an E3 ubiquitin-protein ligase, is involved in targeting proteins for degradation, a fundamental process for protein quality control and signal transduction; therefore, rs10519584 could impact protein turnover and cellular homeostasis. These genetic associations with intermediate traits often exhibit stronger signals due to their direct proximity to causative variants. [7]
Beyond protein-coding genes, variants associated with long intergenic non-coding RNAs (lncRNAs) and pseudogenes also contribute to genetic regulation. _LINC01737_ and _LINC03085_ are lncRNAs, which are known to regulate gene expression through various mechanisms, including chromatin modification and transcriptional control; variants like rs9651127 (associated with _LINC01737_) and rs11882251 (associated with _LINC03085_) could influence the expression levels or regulatory functions of these lncRNAs, affecting downstream gene networks. Pseudogenes, such as _RPL7AP79_, _RPL17P35_, _CYP2C61P_, _NEK4P3_, _MYL6P3_, and _ERVK-28_, while often non-functional copies of active genes, can sometimes play regulatory roles by acting as microRNA sponges or producing small regulatory RNAs. Variants like rs1560294 (near _RPL7AP79_ and _ALX4_), rs10995995 (near _RPL17P35_ and _CYP2C61P_), and rs1949063 (near _NEK4P3_ and _MYL6P3_) could impact the transcription or stability of these pseudogenes, potentially modulating the expression of their functional counterparts or other genes. _ALX4_, a transcription factor, is involved in developmental processes, and rs1560294 could specifically affect its regulatory elements, thereby influencing developmental pathways. [8]
Defining Gene Expression Attributes and Their Quantification
Gene expression attributes refer to the measurable levels of RNA transcripts or their corresponding protein products, reflecting the dynamic activity of specific genes within biological systems. [1] These attributes are considered quantitative traits, exhibiting continuous variation across individuals and populations. Operationally, the quantification of these attributes involves molecular techniques such as determining mRNA expression levels, often utilizing platforms like Illumina HumanHT-12 Expression BeadChips from biological samples such as whole blood. [1] Similarly, protein expression levels, or "relative protein abundances," are meticulously quantified using specialized assays, exemplified by methods provided by SomaLogic Inc.. [7] To ensure robust phenotypes for genetic association studies, raw expression data are typically subjected to normalization, such as natural log-transformation, and adjusted for confounding variables including age, sex, body mass index, disease states, and genetic principal components. [7] Further processing, like rank-inverse normalization, ensures that the data meet the statistical assumptions required for subsequent analyses. [9]
Classification and Conceptual Frameworks in Genetic Studies
Gene expression attributes are frequently categorized based on their genomic relationship to associated genetic variants, providing a framework for understanding regulatory mechanisms. An "expression quantitative trait locus" (eQTL) specifically denotes a genomic region, often identified as a Single Nucleotide Polymorphism (SNP), that significantly influences the expression level of a particular gene. [1] These eQTLs are further classified into "cis-associations" when the influencing SNP is located in close genomic proximity, generally within 10 megabases (Mb) of the gene's boundaries, suggesting a direct regulatory effect on the gene. Conversely, "trans-associations" describe SNPs that exert their influence on gene expression from more distant genomic locations, implying indirect or network-mediated regulatory pathways. [7] The study of these attributes predominantly employs a dimensional approach, treating expression levels as continuous variables rather than discrete categories, which facilitates the identification of subtle genetic influences on physiological processes and their linkages to complex traits or disease endpoints. [7] Genome-wide association studies (GWAS) serve as the primary methodology for discovering these genetic associations, systematically analyzing millions of SNPs across the genome to pinpoint variants correlated with variations in gene expression attributes. [10]
Standardized Terminology and Data Quality Control
The field employs a precise lexicon to describe genetic variants and their analysis. Key terms include "Single Nucleotide Polymorphism" (SNP), representing the most common type of genetic variation interrogated, and "minor allele frequency" (MAF), which quantifies the prevalence of the less common allele within a population. [3] The principle of "Hardy-Weinberg equilibrium" (HWE) is a foundational concept used to assess genotype frequencies and ensure the quality of genetic data. [3] Genomic regions identified through GWAS that harbor genetic variants associated with an attribute are termed "genomic risk loci." Within these loci, "sentinel SNPs" are the most statistically significant variants, "lead SNPs" are independent of other significant SNPs, and "candidate SNPs" are those in linkage disequilibrium with identified independent SNPs. [2] Rigorous quality control (QC) criteria are paramount for genetic data to ensure reliability and prevent spurious associations. These criteria include filtering SNPs based on minimum call rates (e.g., >95%), MAF thresholds (e.g., >1% to >10%, depending on the study), and adherence to HWE (e.g., P > 10^-6). [3] Variants with low imputation quality scores (e.g., INFO < 0.7) or insufficient minor allele counts (e.g., < 8) are also routinely excluded. [9] Such stringent filtering is critical before functional annotation, using tools like ANNOVAR, CADD, and RegulomeDB, which interpret the functional consequences and regulatory potential of identified variants. [2]
Statistical Thresholds and Significance Criteria
Establishing robust statistical significance for associations with gene expression attributes necessitates stringent thresholds to correct for the immense number of tests performed across the genome. A widely accepted "genome-wide significance threshold" for GWAS is a P-value less than 5 x 10^-8, a value initially proposed based on Bonferroni correction for testing approximately one million independent SNPs. [11] For more comprehensive analyses, such as those involving both the genome and proteome, even stricter Bonferroni-corrected thresholds are applied, for instance, P < 8.72 x 10^-11, which accounts for the total number of SNPs and protein probes evaluated. [7] Beyond initial discovery, replication studies employ their own predefined significance levels, such as P < 1.08 x 10^-4, to validate initial findings and ensure their reproducibility. [7] In gene-based analyses, where individual SNP P-values are aggregated to derive a single test-statistic for a gene, the genome-wide significance threshold is adjusted based on the number of genes tested, for example, P < 2.7 x 10^-6 for 18,297 genes. [2] These rigorous statistical criteria are fundamental for identifying reliable genetic loci that influence gene expression attributes, providing a critical foundation for understanding their roles in health and disease.
Genetic and Epigenetic Control of Gene Expression
Gene expression is a fundamental biological process regulated by a complex interplay of genetic and epigenetic mechanisms, dictating which genes are active and at what levels. Genetic variants, such as single nucleotide polymorphisms (SNPs), can influence transcription factor binding, thereby affecting the rate at which genes are transcribed into RNA. [3] These variations can act as expression quantitative trait loci (eQTLs), impacting the abundance of specific transcripts or proteins across various tissues, including whole blood and different regions of the human brain. [1] Beyond protein-coding genes like TEP1, PDZD9, MPP4, and UQCRC2, non-coding RNAs such as miRNA-27a, miRNA24-2, LOC284454, and miRNA-23a also play crucial regulatory roles, often by modulating the stability or translation of messenger RNA. [3]
Epigenetic modifications, such as DNA methylation, add another layer of control without altering the underlying DNA sequence. For instance, methylation of the MGMT gene promoter can significantly impact its activity, influencing cellular responses and disease susceptibility. [12] The genetic architecture of the human brain's transcriptome and epigenome integrates these regulatory layers, revealing how inherited variations can influence both gene expression and epigenetic marks. [13] Furthermore, chromatin interaction mapping identifies significant interactions between genomic regions, linking candidate SNPs to genes based on their proximity to promoter regions and highlighting distal regulatory effects on gene expression. [2]
Molecular Machinery and Cellular Processes
Cellular functions rely on intricate molecular machinery and processes, many of which are directly influenced by gene expression attributes. The spliceosome, a complex ribonucleoprotein, is essential for RNA splicing, a critical step in gene expression where non-coding introns are removed from pre-mRNA to produce mature messenger RNA. [14] Other ribonucleoprotein complexes are also integral to various aspects of RNA metabolism, from transcription to translation and degradation. [14] These complexes ensure the proper processing and function of genetic information within the cell.
Beyond RNA processing, gene expression attributes also govern fundamental cellular activities such as cell-cell adhesion, which is vital for tissue integrity and communication. [14] Cellular proliferation, a tightly regulated process, is positively controlled by specific gene expression patterns that drive cell division and growth. [14] The formation of cell projections, critical for cell migration and interaction with the extracellular matrix, is another attribute influenced by gene expression. [14] Moreover, the maintenance of chromosomes, a cell cycle pathway, is crucial for ensuring genetic stability during cell division. [3]
Signaling Pathways and Metabolic Regulation
Cellular signaling pathways act as communication networks within and between cells, translating external and internal cues into specific cellular responses. The activation of JNK (c-Jun N-terminal kinases) activity, for example, is a key component of stress response pathways, impacting cell fate decisions such as apoptosis and inflammation. [14] Similarly, the GnRH (gonadotropin-releasing hormone) pathway activates ERK1/2 (extracellular signal-regulated kinases), leading to the induction of transcription factors like c-fos and the expression of hormones such as LHbeta, which are crucial for reproductive function. [15]
Metabolic processes, which encompass all chemical reactions involved in maintaining the living state of cells and organisms, are also tightly regulated by gene expression. Enzymes like phosphoric ester hydrolases, which catalyze the breakdown of phosphoric esters, are central to various metabolic pathways, including energy production and signal transduction. [14] Genetic variants can influence metabolic traits and the overall metabolome, impacting an individual's metabolic profile. [16] These integrated signaling and metabolic networks illustrate how gene expression attributes orchestrate the dynamic physiological balance within an organism.
Tissue-Specific Gene Expression and Systemic Impact
Gene expression patterns exhibit remarkable specificity across different tissues and organs, contributing to their unique functions and the overall systemic consequences. In the central nervous system, for instance, genetic factors influence protein expression patterns, which are critical for neurodevelopment and brain function. [17] Variations in gene expression in brain regions like the anterior cingulate cortex (ACC) and posterior cingulate cortex (PCC) have been linked to microstructural abnormalities observed in conditions like schizophrenia. [3]
The hypothalamic-pituitary-gonadal (HPG) axis, a key endocrine system, demonstrates how tissue-specific gene expression, particularly of hormones and receptors, regulates systemic processes such as menstrual cycle length and pubertal timing. [2] Moreover, gene expression in chondrocytes, the cells responsible for cartilage formation, can influence bone growth and the development of structures like the spinal canal. [18] Beyond specific organs, systemic effects are evident in conditions like hypertrophic cardiomyopathy, where gene expression changes contribute to cardiac remodeling. [14] The impact of gene expression extends to diverse traits, including skin barrier function and human ear morphology, highlighting its pervasive influence on physiological processes and phenotypic characteristics across the body. [19]
Pathways and Mechanisms
The regulation of gene expression attribute involves a complex interplay of cellular signaling, metabolic pathways, and diverse regulatory mechanisms, integrated at a systems level to maintain cellular function and organismal homeostasis. Genetic variations can influence these pathways, impacting protein abundance and contributing to various disease states.
Cellular Signaling and Transcriptional Control
Cellular signaling pathways initiate responses that profoundly influence gene expression. Receptor tyrosine kinases, such as Tie-1, when overexpressed in endothelial cells, upregulate adhesion molecules, demonstrating a direct link between receptor activation and downstream gene expression changes. [20] Similarly, cyclic strain regulates the Notch/CBF-1 signaling pathway in endothelial cells, which is critical for angiogenic activity. [21] The formation of VEGF receptor 2 and 3 heterodimers is essential for angiogenic sprouts, and VEGF can induce Shc association with vascular endothelial cadherin, suggesting a feedback mechanism that modulates VEGF receptor-2 signaling and thus downstream gene expression. [22]
Intracellular signaling cascades, including those involving MAPK3 and the activation of ERK1/2 by GnRH, lead to the induction of specific protein expressions like c-fos and LHbeta. [1] Genetic inactivation of ERK1 and ERK2 in chondrocytes, for instance, promotes bone growth, highlighting their role in developmental processes regulated through gene expression. [18] Furthermore, genetic variants can directly influence the levels of transcription factors and cell signaling proteins. [23] SNPs have been shown to play significant roles in transcription factor binding and transcription-enhancing activities, particularly in tissues relevant to neurodevelopment and immunology. [3] The study of cross-species transcription factor binding site patterns offers insights into the molecular basis of disease mechanisms. [24]
Metabolic Control and Bioenergetics
Metabolic pathways are tightly linked to gene expression, governing energy metabolism, biosynthesis, and catabolism. A variant in PPP4R3A, for example, has been found to protect against Alzheimer-related metabolic decline, illustrating how specific genetic changes can influence metabolic health. [5] The protein phosphatase 4 catalytic subunit (PP4C), also known as SMEK, is a key regulator of hepatic gluconeogenesis, a critical process for maintaining blood glucose homeostasis. [25] Genetic loci identified in studies on fasting glucose homeostasis highlight their impact on the risk of type 2 diabetes, further demonstrating the genetic control over metabolic regulation. [26]
Beyond glucose metabolism, genetic variations influence human metabolism broadly, including fatty acid desaturase activity in serum and adipose tissue, which is associated with insulin sensitivity. [27] The effect of Alzheimer's disease risk genes on FDG PET brain metabolism underscores the connection between genetic predisposition and metabolic profiles relevant to neurological diseases. [28] An epigenome-wide association study investigating blood serum metabolic traits reveals an intricate relationship between epigenetics and metabolic regulation, suggesting that both genetic and epigenetic factors control metabolic flux and cellular energy balance. [29]
Post-Transcriptional and Epigenetic Mechanisms
Gene expression attribute is also modulated by regulatory mechanisms acting after transcription, including post-transcriptional control, protein modification, and epigenetic changes. Conditional eQTL analysis has revealed allelic heterogeneity of gene expression, indicating that genetic variants can differentially affect gene expression depending on specific cellular contexts. [30] The tissue-specific genetic control of splicing is a crucial post-transcriptional mechanism with significant implications for complex traits, allowing for diverse protein isoforms from a single gene. [31] Non-coding micro-RNA genes, such as miRNA-27a, miRNA24-2, and miRNA-23a, along with protein-coding genes like TEP1, PDZD9, MPP4, and UQCRC2, contribute to the intricate network of gene expression regulation. [3]
Protein modification, particularly ubiquitination, plays a vital role in protein stability and function. Nedd4 and Nedd4-2 are prominent ubiquitin ligases active in neurons, controlling protein degradation and signaling. [32] The Drosophila ortholog of human CDCrel-1, Septin 4, accumulates in parkin mutant brains and is functionally linked to the Nedd4 E3 ubiquitin ligase, highlighting the conserved mechanisms of protein ubiquitination and its relevance to neurological conditions. [33] Protein phosphatase activity also contributes to the post-translational regulation of protein function. [34]
Epigenetic mechanisms, such as DNA methylation, are fundamental to gene regulation. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate the expression of p53-repressed promoters. [12] DNA damage, homology-directed repair, and SIRT1-dependent onset of DNA methylation in CpG islands can initiate gene silencing, demonstrating how cellular stress and repair pathways can lead to stable changes in gene expression patterns. [35] Integrative analyses of human epigenomes provide a comprehensive view of these regulatory layers and their impact on gene expression. [36]
Systems-Level Integration and Disease Pathogenesis
The gene expression attribute is a product of systems-level integration, where various pathways crosstalk and form complex networks. Genetic variations, acting as natural experiments, reveal that blood plasma levels of many proteins are under substantial genetic control, with multiple association signals converging to impact key protein levels within intricate protein networks. [7] Gene networks are associated with complex traits, illustrating how a systems genetics approach can uncover the interplay of multiple genes in biological processes. [37] Identified biological pathways, such as cell-cell adhesion, cell projection, and positive regulation of cell proliferation, underscore the broad cellular functions influenced by these integrated networks. [34]
Hierarchical regulation, encompassing cis- and trans-regulatory effects across diverse tissues, contributes to an xQTL map that integrates the genetic architecture of the transcriptome and epigenome. [38] This multi-layered regulation results in emergent properties that define cellular and organismal phenotypes. The comprehensive annotation of genetic variants, including regulatory elements like eQTLs, meQTLs, and mQTLs, and their association with disease risk, provides a framework for understanding how genetic variations contribute to disease pathogenesis. [7] Functional annotation of genetic variants helps estimate their pathogenicity and identify potential therapeutic targets, offering avenues for precision medicine. [39]
Clinical Relevance
Gene expression attributes, encompassing both mRNA and protein levels, offer significant insights into human health and disease, serving as crucial indicators for various clinical applications. Understanding the genetic factors influencing these attributes is vital for advancing personalized medicine, improving diagnostic precision, and identifying novel therapeutic targets.
Diagnostic and Prognostic Biomarkers
Gene expression attributes hold considerable potential as diagnostic and prognostic biomarkers, aiding in risk assessment and the prediction of disease outcomes. For instance, observational studies have linked higher plasma levels of MMP-12 to an increased risk of recurrent cardiovascular events, suggesting its utility as a marker for adverse cardiac outcomes. [9] However, genetic studies reveal a more complex picture, where a genetic predisposition to elevated MMP-12 levels is associated with a decreased risk of coronary disease and large artery atherosclerotic stroke. [9] This highlights that while observational findings may indicate associations, genetic analyses of gene expression attributes can provide a more robust understanding of causal relationships and long-term implications, free from many confounding factors inherent in observational epidemiology. [9] Similarly, a major Alzheimer's disease (AD) risk variant, rs4420638, is associated with increased APOE protein levels, demonstrating how specific gene expression patterns can be directly linked to disease risk and progression. [7]
Precision Medicine and Therapeutic Targets
The study of gene expression attributes is instrumental in the development of precision medicine approaches and the prioritization of therapeutic targets. The example of MMP-12 illustrates this well; while MMP-12 inhibitors are being explored as treatments for chronic obstructive pulmonary disease, and due to observational links, also for cardiovascular disease, genetic insights into MMP-12 expression are critical. [9] The genetic finding that higher MMP-12 levels may be protective against coronary disease suggests that a nuanced, genetically informed approach is necessary for treatment selection, potentially guiding which patient populations might benefit from MMP-12 inhibition. [9] Furthermore, research indicates that drugs targeting proteins with human genetic support, often identified through pQTL (protein quantitative trait loci) studies, have a greater likelihood of therapeutic success. [9] This evidence-based approach, where a substantial proportion of pQTL-identified proteins are established drug targets, streamlines the selection of interventions and fosters personalized medicine strategies by focusing on targets with validated genetic links to disease. [9]
Elucidating Disease Mechanisms and Risk Stratification
Analyzing gene expression attributes helps in elucidating underlying disease mechanisms, understanding comorbidities, and improving risk stratification to guide prevention strategies. Methods such as Mendelian Randomization (MR) utilize genetic variants as instrumental variables to assess the causal effect of gene expression attributes, like plasma protein levels, on disease outcomes. [9] This approach is crucial for distinguishing genuine causal links from mere associations, thereby offering a clearer understanding of disease etiology and identifying true risk factors. [9] Multivariable MR analyses further refine this by estimating direct causal effects, accounting for instances where genetic variants may influence multiple proteins or pathways simultaneously. [9] By leveraging these insights, clinicians can identify high-risk individuals and tailor personalized prevention strategies. Additionally, functional annotation and gene set enrichment analyses link changes in gene expression to biologically relevant pathways and potential pathogenicity, providing a comprehensive framework for early intervention and targeted prevention . [2], [4], [34]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs10928182 | ARHGAP15 | gene expression attribute |
| rs9651127 | LINC01737 - COG2 | gene expression attribute |
| rs1560294 | ALX4 - RPL7AP79 | gene expression attribute |
| rs56344002 | NTM | gene expression attribute |
| rs11652075 | CARD14 | Hirschsprung disease psoriasis gene expression attribute |
| rs10995995 | RPL17P35 - CYP2C61P | gene expression attribute |
| rs878085 | SLC35F4 | gene expression attribute |
| rs10519584 | RNF150 | gene expression attribute |
| rs1949063 | NEK4P3 - MYL6P3 | gene expression attribute |
| rs11882251 | LINC03085 - ERVK-28 | gene expression attribute |
Frequently Asked Questions About Gene Expression Attribute
These questions address the most important and specific aspects of gene expression attribute based on current genetic research.
1. Why do I catch every bug, but my friend never does?
Your susceptibility to illness can be influenced by how active certain genes are, especially those involved in your immune system. Variations in these genes can lead to different levels of protective proteins or RNA molecules, making some individuals more prone to developing diseases or infections compared to others.
2. Are my kids doomed to get the same health issues as me?
Not necessarily. While genetic variations that influence gene expression can be passed down and contribute to a predisposition for certain conditions, the exact manifestation of health issues varies greatly. Gene expression levels differ significantly between individuals, even within families, leading to diverse health outcomes.
3. Could a DNA test really tell me about my future health?
Yes, a DNA test can offer insights into your future health. By identifying specific genetic variations that influence gene expression, scientists can predict your individual susceptibility to certain diseases and even suggest more precise diagnostic tools or targeted therapies tailored to your unique genetic profile.
4. Can what I eat or do really change my health destiny?
Absolutely. While your genes provide a blueprint, your daily habits, diet, and environment can significantly influence how those genes are expressed. Understanding your genetic and expression profile allows for personalized interventions, meaning lifestyle choices can be tailored to help manage or mitigate genetic predispositions.
5. Does my ethnic background influence my disease risk?
Yes, your ethnic background can play a role. Genetic associations, including those that affect gene expression, can be highly specific to certain ancestries. This means that risks identified in one population may not directly apply to another, highlighting the importance of diverse research for accurate health predictions.
6. Does my body's "program" for health change with age?
Yes, gene expression patterns can change as you get older. The levels of gene products, like proteins and RNA, are not static and can vary significantly across different life stages. These age-related changes in gene activity can influence your susceptibility to various conditions and how your body functions over time.
7. Why do some health problems target specific body parts?
Different tissues and organs in your body have unique gene expression profiles. Genetic variations can influence gene activity differently across distinct human tissues. This specificity means that certain genetic influences might predominantly impact, for example, brain tissue in neurodegenerative conditions, or cells related to immunology, leading to localized health problems.
8. Does stress actually impact my genes and health?
While "stress" isn't directly mentioned as altering genes, various factors can influence gene expression, particularly in critical tissues like the brain. Research shows how gene expression in areas like the prefrontal cortex can be implicated in conditions like Alzheimer's, suggesting that environmental and physiological factors can indeed affect how genes are active, impacting overall health.
9. My sibling is so different from me; how can that be?
Even with shared parental genetics, the precise levels of gene expression can vary significantly between individuals. This means that while you share many genes, how active those genes are in your cells can differ, leading to diverse attributes and phenotypes, or unique traits and characteristics, for each sibling.
10. Can my lifestyle truly overcome my genetic health risks?
Understanding your genetic risks allows for targeted strategies. While you can't change your genes, knowing how specific genetic variations influence gene expression helps in developing personalized interventions. These tailored approaches, which include lifestyle modifications, can significantly help manage or reduce the impact of your genetic predispositions.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Cousminer, D. L. et al. "Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and childhood adiposity." Hum Mol Genet, 2013. PMID: 23449627.
[2] Laisk, T, et al. "Large scale meta-analysis highlights the hypothalamic-pituitary-gonadal (HPG) axis in the genetic regulation of menstrual cycle length." Human Molecular Genetics, vol. 27, no. 18, 2018, pp. 3241-3251.
[3] Ren, H. Y. et al. "The common variants implicated in microstructural abnormality of first episode and drug-naïve patients with schizophrenia." Sci Rep, 2017. PMID: 28924203.
[4] Karlsson Linner, R et al. "Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences." Nat Genet, 2019. PMID: 30643258.
[5] Christopher, L. et al. "A variant in PPP4R3A protects against alzheimer-related metabolic decline." Ann Neurol, 2017. PMID: 29130521.
[6] Shah, H. R., et al. "Gene expression elucidates functional impact of polygenic risk for schizophrenia." Nature Neuroscience, vol. 19, no. 11, 2016, pp. 1442–1453.
[7] Suhre, K, et al. "Connecting genetic risk to disease end points through the human blood plasma proteome." Nature Communications, vol. 8, 2017, p. 14357.
[8] Felsky, Dolores, et al. "Neuropathological correlates and genetic architecture of microglial activation in elderly human brain." Nature Communications, vol. 10, no. 1, 2019, p. 402.
[9] Sun, Bao B., et al. "Genomic atlas of the human plasma proteome." Nature, vol. 558, no. 7711, 2018, pp. 585-591.
[10] Stein, JL. "Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search." Mol Psychiatry, 2011. PMID: 21502949.
[11] Fornage, M et al. "Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium." Ann Neurol, 2011. PMID: 21681796.
[12] Leng, S. et al. "15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers." J Natl Cancer Inst, 2015. PMID: 25713168.
[13] Ng, B. et al. "An xQTL map integrates the genetic architecture of the human brain’s transcriptome and epigenome." Nat. Neurosci., vol. 20, 2017, pp. 1418–1426.
[14] "ACTIVATION_OF_JNK_ACTIVITY." MSigDB, Broad Institute. http://www.broadinstitute.org/gsea/msigdb/cards/ACTIVATION_OF_JNK_ACTIVITY.html.
[15] Chen, J., et al. "GnRH activates ERK1/2 leading to the induction of c-fos and LHbeta protein expression in LbetaT2 cells." Mol. Endocrinol., vol. 16, 2002, pp. 331–343.
[16] Inouye, M., et al. "Metabonomic, transcriptomic, and genomic variation of a population cohort." Mol Syst Biol, vol. 6, 2010, p. 441.
[17] Sasayama, D., et al. "Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome." Hum Mol Genet, vol. 26, no. 3, 2017, pp. 630-639.
[18] Sebastian, A. et al. "Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal." J. Orthop. Res., vol. 29, 2011, pp. 375–379.
[19] Zhang, Ming, et al. "A Genome-Wide Association Study of Basal Transepidermal Water Loss Finds that Variants at 9q34.3 Are Associated with Skin Barrier Function." J Invest Dermatol, vol. 138, no. 4, 2018, pp. 794-802.
[20] Chan, B. et al. "Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules." Biochem. Biophys. Res. Commun., vol. 371, 2008, pp. 475–479.
[21] Morrow, D. et al. "Cyclic strain regulates the Notch/CBF-1 signaling pathway in endothelial cells: Role in angiogenic activity." Arterioscler. Thromb. Vasc. Biol., vol. 27, 2007, pp. 1289–1296.
[22] Nilsson, I. et al. "VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts." EMBO J., vol. 29, 2010, pp. 1377–1388.
[23] Hause, R. J. et al. "Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels." Am. J. Hum. Genet., vol. 95, 2014, pp. 194–208.
[24] Claussnitzer, M. et al. "Leveraging cross-species transcription factor binding site patterns: From diabetes risk loci to disease mechanisms." Cell, vol. 156, 2014, pp. 343–358.
[25] Yoon, Y-S. et al. "Suppressor of MEK null (SMEK)/protein phosphatase 4 catalytic subunit (PP4C) is a key regulator of hepatic gluconeogenesis." Proc Natl Acad Sci., vol. 107, no. 41, 2010, pp. 17704–9.
[26] Dupuis, J. et al. "New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk." Nat Genet., vol. 42, no. 2, 2010, pp. 105–16.
[27] Illig, T. et al. "A genome-wide perspective of genetic variation in human metabolism." Nat. Genet., vol. 42, 2010, pp. 137–141.
[28] Stage, E. et al. "The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism." Alzheimer’s Dement (Amst), vol. 5, 2016, pp. 53–66.
[29] Petersen, Anne-Katrin K., et al. "Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits." Hum Mol Genet, vol. 23, no. 2, 2014, pp. 532-540.
[30] Jansen, R. et al. "Conditional eQTL analysis reveals allelic heterogeneity of gene expression." Hum Mol Genet., vol. 26, no. 8, 2017, pp. 1444–1451.
[31] Heinzen, E. L. et al. "Tissue-specific genetic control of splicing: implications for the study of complex traits." PLoS Biol., vol. 6, 2008, p. e1.
[32] Donovan, P., and Poronnik, P. "Nedd4 and Nedd4-2: Ubiquitin ligases at work in the neuron." Int J Biochem Cell Biol, vol. 45, no. 3, 2012, pp. 706–710.
[33] Muñoz-Soriano, V. et al. "Septin 4, the Drosophila ortholog of human CDCrel-1, accumulates in parkin mutant brains and is functionally related to the Nedd4 E3 ubiquitin ligase." J Mol Neurosci, vol. 48, no. 1, 2012, pp. 136–143.
[34] Li, J et al. "Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort." Biomed Res Int, 2015. PMID: 26421299.
[35] O’Hagan, H. M. et al. "Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island." PLoS Genet., vol. 4, no. 8, 2008, p. e1000155.
[36] Roadmap Epigenomics Consortium et al. "Integrative analysis of 111 reference human epigenomes." Nature, vol. 518, 2015, pp. 57–74.
[37] Park, C. C. et al. "Gene networks associated with conditional fear in mice identified using a systems genetics approach." BMC Syst Biol, vol. 5, 2011, p. 43.
[38] Grundberg, E. et al. "Mapping cis- and trans-regulatory effects across multiple tissues in twins." Nat. Genet., vol. 44, 2012, pp. 1084–1089.
[39] Kircher, M. et al. "A general framework for estimating the relative pathogenicity of human genetic variants." Nat. Genet., vol. 46, 2014, pp. 310–315.